Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (251-260 of 352) with videos related to

Pageof 36
Sort By:
Gastroenterology|June 18, 2013
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2020
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trialRaja Atreya, Laurent Peyrin-Biroulet, Andrii Klymenko, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 26, 2024
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 TrialsJean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, et al.
Crohn'S & Colitis 360|June 29, 2026
Stoma formation and associated risk factors in patients with Crohn's disease in an Austrian tertiary referral hospital: a retrospective explorative study of long-term follow-upChristian Primas, Stefan Riss, Jagoda Pokryszka, et al.
Journal of Crohn'S & Colitis|January 21, 2012
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programmeMarc Ferrante, Konstantinos Karmiris, Evan Newnham, et al.
Journal of Crohn'S & Colitis|March 9, 2026
Position Paper: IOlBD Evidence-based Consensus on the Use of Artificial Intelligence for Assessment of Endoscopic and Histologic Endpoints in Clinical Trials of Inflammatory Bowel DiseaseAxel Dignass, Neeraj Narula, Krishan Pratap, et al.
Journal of Crohn'S & Colitis|April 25, 2015
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD InitiativeSilvio Danese, Gionata Fiorino, Jean-Yves Mary, et al.
The Journal of Biological Chemistry|December 14, 2001
Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysisNorbert Degousee, Farideh Ghomashchi, Eva Stefanski, et al.
Gastroenterology|June 6, 2013
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Journal of Crohn'S & Colitis|February 14, 2012
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensusWalter Reinisch, Gert Van Assche, Ragnar Befrits, et al.
Pageof 36

Showing results (251-260 of 352) with videos related to

Sort By:
Pageof 36
Gastroenterology|June 18, 2013
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2020
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trialRaja Atreya, Laurent Peyrin-Biroulet, Andrii Klymenko, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 26, 2024
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 TrialsJean-Frédéric Colombel, Ana P Lacerda, Peter M Irving, et al.
Crohn'S & Colitis 360|June 29, 2026
Stoma formation and associated risk factors in patients with Crohn's disease in an Austrian tertiary referral hospital: a retrospective explorative study of long-term follow-upChristian Primas, Stefan Riss, Jagoda Pokryszka, et al.
Journal of Crohn'S & Colitis|January 21, 2012
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programmeMarc Ferrante, Konstantinos Karmiris, Evan Newnham, et al.
Journal of Crohn'S & Colitis|March 9, 2026
Position Paper: IOlBD Evidence-based Consensus on the Use of Artificial Intelligence for Assessment of Endoscopic and Histologic Endpoints in Clinical Trials of Inflammatory Bowel DiseaseAxel Dignass, Neeraj Narula, Krishan Pratap, et al.
Journal of Crohn'S & Colitis|April 25, 2015
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD InitiativeSilvio Danese, Gionata Fiorino, Jean-Yves Mary, et al.
The Journal of Biological Chemistry|December 14, 2001
Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysisNorbert Degousee, Farideh Ghomashchi, Eva Stefanski, et al.
Gastroenterology|June 6, 2013
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Journal of Crohn'S & Colitis|February 14, 2012
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensusWalter Reinisch, Gert Van Assche, Ragnar Befrits, et al.
Pageof 36